Which company does Entrectinib come from?

The U.S. Food and Drug Administration (FDA)granted accelerated approval, priority review, breakthrough therapy and orphan drug designation to entrectinib (Entrectinib), sold under the trade name Rozlytrek, and the approval was granted to Genentech ( Genentech, Inc.), common dosage forms are capsules and oral pills. It is a tumor-agnostic drug. It is a selective tyrosine kinase inhibitor designed to inhibit the kinase activity of TRKA/B/C and ROS1 proteins, whose activation fusion drives the proliferation of certain types of cancer. It has been approved as a once-daily oral drug for the treatment of NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer.